On December 2, Hengrui Pharmaceutical issued an announcement that as of November 30, the company has repurchased about 12 million shares of its own shares, with a transaction price range of 27.
08-34.
9 yuan per share, and a total amount of 398 million yuan has been paid to boost market confidence
.
It is reported that at the beginning of this year, Hengrui Pharmaceutical launched a share repurchase, and at the same time as the release of the 2022 half-year report, it announced that the previously repurchased shares will be used for the new employee stock ownership plan, and it is expected that more than 1,000 employees will receive incentives of no more than 12 million shares
.
According to the plan, the performance evaluation indicators are divided into performance evaluation indicators and individual performance evaluation indicators, and the performance evaluation indicators include innovative drug sales revenue, the number of new molecular entity IND (new drug clinical trial application) approved, and the number of NDA applications (new drug marketing authorization) declared and accepted by innovative drugs (including new indications
).
Analysts believe that this employee stock ownership plan with innovative drug business as the assessment item can also be interpreted as Hengrui Pharmaceutical's innovative drug planning goals in the next few years, reflecting Hengrui Pharmaceutical's confidence and determination
in innovation.
It is understood that in the process of transforming into an innovative pharmaceutical company, Hengrui Pharmaceutical's R&D investment has increased year by year, rapidly climbing from 1.
18 billion yuan in 2016 to 6.
203 billion yuan
in 2021.
In the first three quarters of 2022, in the first three quarters of this year, Hengrui Pharmaceutical's R&D expenses were 3.
498 billion yuan, and the R&D expenditure was 1.
323 billion yuan, with a total R&D investment of 4.
821 billion yuan, a year-on-year increase of 9.
52%.
With high R&D investment, Hengrui Pharmaceutical has established a huge R&D pipeline
.
According to the data, Hengrui Pharmaceutical has carried out
more than 260 clinical projects at home and abroad.
There are more than 60 innovative drugs under development in the R&D pipeline, covering anti-tumor, diabetes and other fields
.
Some institutions predict that by 2025, Hengrui Pharmaceutical is expected to form a matrix of 25+ innovative drugs, with a revenue volume of more than 25 billion yuan
.
In recent years, while Hengrui Pharmaceutical has increased investment in R&D, innovative drugs have also entered the harvest period, and up to now, its innovative drugs have been approved for marketing to reach 11
.
Among them, in July this year, Hengrui Pharmaceutical's 11th listed innovative drug, the self-developed androgen receptor (AR) inhibitor Erien (Revirutamide tablets), issued the first prescription in the country, bringing new treatment options
for metastatic hormone-sensitive prostate cancer patients with high tumor burden in China.
In addition, Hengrui Pharmaceutical has accelerated the pace
of industrial investment while increasing research and development.
The industry said that relying solely on its own research and development strength is limited, and Hengrui Pharmaceutical has also accelerated the pace
of industrial investment.
Data show that at the beginning of 2021, Hengrui Pharmaceutical's long-term equity investment was only 60 million yuan, and by the end of September 2022, it had increased to 493 million yuan, an increase of 7.
22 times
in less than two years.
It is reported that Hengrui Pharmaceutical issued an announcement in early June that it intends to sign an agreement with its holding subsidiary Shengdi Investment and Hengrui Group to establish a private equity enterprise, with a total capital of 2.
01 billion yuan, in order to enhance the company's capital operation ability and deepen the company's industrial layout
.
In addition, data show that Hengrui Pharmaceutical completed 4 industrial investments
in 2021.
For example, in February 2021, Hengrui Pharmaceutical issued an announcement that it intends to subscribe for 7.
8125 million B-series preferred shares of Shanghai Yingli Pharmaceutical with self-financing of 20 million US dollars; in August 2021, Hengrui Pharmaceutical spent 1.
4 billion yuan to introduce Dalian Wanchunbulin's first-in-class new drug GEF-H1 activator Plinabulin; ten days later, it paid 30 million US dollars (equivalent to 200 million yuan).
Obtained the exclusive commercialization rights of the third-generation CD20 monoclonal antibody MIL62 in China; In November 2021, Hengrui Pharmaceutical reached an agreement with CStone to introduce the anti-CTLA-4 monoclonal antibody CS1002 in Greater China
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
